157 related articles for article (PubMed ID: 32569190)
1. Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer.
Zhang B; Wang L; Liu Z; Shao B; Jiang W; Shu P
Medicine (Baltimore); 2020 Jun; 99(25):e20617. PubMed ID: 32569190
[TBL] [Abstract][Full Text] [Related]
2. Integrated Analysis Identifies an Immune-Based Prognostic Signature for the Mesenchymal Identity in Gastric Cancer.
Peng D; Gu B; Ruan L; Zhang X; Shu P
Biomed Res Int; 2020; 2020():9780981. PubMed ID: 32352015
[TBL] [Abstract][Full Text] [Related]
3. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
[TBL] [Abstract][Full Text] [Related]
4. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer.
Matsuyama T; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kawano T; Uetake H; Goel A
Mol Cancer; 2019 Feb; 18(1):19. PubMed ID: 30717807
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of an autophagy-based signature in colorectal cancer.
Wang L; Jiang X; Zhang X; Shu P
Medicine (Baltimore); 2021 Apr; 100(13):e25148. PubMed ID: 33787596
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of an immune prognostic signature in colorectal cancer.
Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
[TBL] [Abstract][Full Text] [Related]
8. Gene pair based prognostic signature for colorectal colon cancer.
Shu P; Wu J; Tong Y; Xu C; Zhang X
Medicine (Baltimore); 2018 Oct; 97(42):e12788. PubMed ID: 30334969
[TBL] [Abstract][Full Text] [Related]
9. An Individualized EMT-Related Gene Signature to Predict Recurrence-Free Survival in Stage II/III Colorectal Cancer Patients.
Zhang W; Zhang X; Zhao D; Hu M; Ge X; Xia L
Dig Dis Sci; 2022 Nov; 67(11):5116-5126. PubMed ID: 35094253
[TBL] [Abstract][Full Text] [Related]
10. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
11. A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer.
Kim SK; Kim SY; Kim CW; Roh SA; Ha YJ; Lee JL; Heo H; Cho DH; Lee JS; Kim YS; Kim JC
Exp Mol Med; 2019 Oct; 51(10):1-12. PubMed ID: 31578316
[TBL] [Abstract][Full Text] [Related]
12. Integrative network analysis identifies an immune-based prognostic signature as the determinant for the mesenchymal subtype in epithelial ovarian cancer.
Sheng M; Tong H; Lu X; Shanshan N; Zhang X; Reddy BA; Shu P
Medicine (Baltimore); 2020 Oct; 99(41):e22549. PubMed ID: 33031300
[TBL] [Abstract][Full Text] [Related]
13. KRT17 as a prognostic biomarker for stage II colorectal cancer.
Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
[TBL] [Abstract][Full Text] [Related]
14. Immune-related gene signature in predicting prognosis of early-stage colorectal cancer patients.
Ke J; Liu XH; Jiang XF; He Z; Xiao J; Zheng B; Chen YF; Cai ZR; Zheng XB; Zou YF; Lan P; Wu XJ; Gao F
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e62-e70. PubMed ID: 32863096
[TBL] [Abstract][Full Text] [Related]
15. Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer.
Liu Z; Lu T; Wang Y; Jiao D; Li Z; Wang L; Liu L; Guo C; Zhao Y; Han X
J Cell Mol Med; 2021 Jul; 25(14):6874-6886. PubMed ID: 34101338
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Novel Five-Gene Signature as a Prognostic and Diagnostic Biomarker in Colorectal Cancers.
Ghatak S; Mehrabi SF; Mehdawi LM; Satapathy SR; Sjölander A
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054980
[TBL] [Abstract][Full Text] [Related]
17. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
[TBL] [Abstract][Full Text] [Related]
18. Identification of an EMT-related Gene Signature Predicting Recurrence in Stage II/III Colorectal Cancer: A Retrospective Study in 1780 Patients.
Ren H; Bösch F; Pretzsch E; Jacob S; Westphalen CB; Walter Holch J; Werner J; Angele MK
Ann Surg; 2022 Nov; 276(5):897-904. PubMed ID: 35880752
[TBL] [Abstract][Full Text] [Related]
19. A Prognostic Immunoscore for Relapse-Free Survival Prediction in Colorectal Cancer.
Wang H; Xu F; Zhang M; Liu J; Wang F; Zhao Q
DNA Cell Biol; 2020 Jul; 39(7):1181-1193. PubMed ID: 32397747
[TBL] [Abstract][Full Text] [Related]
20. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
